Vebreltinib plus furmonertinib for EGFR‑TKI–resistant NSCLC with c‑MET amplification

The Open-Label, Multicenter Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Vebreltinib Combined With Furmonertinib in Locally Advanced or Metastatic NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

This study tests whether giving vebreltinib together with furmonertinib can help people with advanced NSCLC that developed c‑MET amplification after their EGFR‑targeted therapy stopped working.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Peking University Cancer Hospital & Institute (Academic / other)
• Drugs / interventions: chemotherapy, radiation, vebreltinib, furmonertinib
• Locations: 12 sites (Neimeng, Neimeng and 11 other locations)
• Trial ID: NCT07087223 on ClinicalTrials.gov

What this trial studies

This is a Phase Ib/II trial enrolling adults with locally advanced or metastatic NSCLC who have EGFR‑sensitizing mutations and developed c‑MET amplification after progression on EGFR‑TKI therapy. Phase Ib uses a 3+3 dose‑escalation design (100, 150, 200 mg BID of vebreltinib) to define DLTs, the MTD, and an RP2D, followed by dose expansion cohorts of about 10 subjects each. Phase II will use the selected dose(s) to measure anti-tumor activity such as overall response rate and progression‑free survival. Safety, tolerability, and recommended dosing of the combination with furmonertinib are central endpoints throughout the study.

Who should consider this trial

Good fit: Adults (≥18) with unresectable locally advanced or metastatic NSCLC, documented EGFR sensitizing mutations, documented c‑MET amplification, and disease progression after prior EGFR‑TKI therapy (with prior objective benefit and ≤1 prior chemotherapy regimen allowed) are the intended participants.

Not a fit: Patients without c‑MET amplification, those who never derived clinical benefit from prior EGFR‑TKI therapy, or those with medical conditions that preclude targeted therapy are unlikely to benefit from this regimen.

Why it matters

Potential benefit: If successful, the combination could shrink tumors or extend the time without progression for patients with MET‑amplified, EGFR‑TKI–resistant NSCLC and provide a new targeted option for this subgroup.

How similar studies have performed: Other early‑phase studies combining MET inhibitors with EGFR TKIs have shown promising responses in MET‑driven, EGFR‑resistant NSCLC, but large definitive randomized evidence is still limited.

Eligibility criteria

Inclusion Criteria:

1. Fully aware this study and voluntary to sign the informed consent form, and willing and able to comply with the study procedure.
2. Aged ≥18 years, male or female.
3. Patients with histologically or cytologically confirmed unresectable and non-suitable for radical surgery, or concurrent chemoradiotherapy , locally advanced or metastatic (stage IIIB, IIIC or IV) NSCLC;
4. Documented EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).
5. Disease progression after prior EGFR-TKI therapy. Participants must meet both of the following 2 criteria:

(1) ≤1 prior chemotherapy regimen allowed besides EGFR-TKI. Combination with anti-angiogenic therapy or PD-1/PD-L1 inhibitors are allowed during EGFR-TKI targeted therapy or chemotherapy.

（2） Objective clinical benefit documented during previous EGFR-TKI therapy, defined by either partial or complete radiological response, or durable stable disease should be greater than 6 months after initiation of EGFR-TKI.

6\. After the last line of treatment before enrollment, progression is confirmed, and blood tests confirm c-Met amplification, or re-biopsy and genetic testing confirm c-Met amplification. Any of the following criteria define c-Met amplification.

1. For tumor tissue samples, FISH detection shows GCN ≥5 and/or MET/CEP7 ≥2 (FISH results from local testing institutions/central laboratories are acceptable);
2. Tissue (wax blocks from pleural effusion centrifugation, if quality-controlled) or blood NGS testing results confirm c-Met amplification with CN ≥2.3 (NGS results from local testing institutions/central laboratories are acceptable for both tissue and blood).

7\. ECOG performance status ≤1. 8. According to RECIST v1.1, the patient must have at least one target lesion as assessed by the investigator.

9\. Laboratory test results must meet the following criteria:

1. Absolute neutrophil count ≥1.5×10⁹/L (without the use of growth factors within 7 days prior to the start of treatment);
2. Hemoglobin ≥90 g/L (without blood transfusion or use of growth factors within 7 days prior to the start of treatment);
3. Platelet count ≥75×10⁹/L (without blood transfusion or use of growth factors within 7 days prior to the start of treatment);
4. Serum total bilirubin ≤1.5×upper limit of normal (ULN);
5. Serum alanine aminotransferase and aspartate aminotransferase ≤3×ULN (for patients with liver metastases, both AST and ALT ≤5×ULN);
6. Creatinine clearance (Ccr) ≥60 mL/min.
7. International normalized ratio (INR) ≤1.5×ULN;
8. Asymptomatic serum amylase ≤Grade 2 (NCI-CTCAE v5.0). For patients with Grade 2 serum amylase abnormalities at the start of the study, it must be confirmed that there are no signs and/or symptoms suggestive of pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal pancreatic imaging results);
9. Serum lipase ≤1.5×ULN. 10. Men with reproductive potential and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 3 months after the last dose of the study drug. Women of childbearing potential must have a negative serum pregnancy test within ≤7 days prior to the first dose of the study drug. This does not apply to female subjects who have undergone sterilization or are postmenopausal.

11\. Expected survival ≥3 months.

Exclusion Criteria:

1. Patients with ALK fusion or ROS1 fusion.
2. Patients with spinal cord compression, leptomeningeal metastasis, or symptomatic brain metastasis that requires an increase in steroid dosage to control central nervous system disease. Patients with symptomatic CNS metastases that have been controlled may be eligible for this trial.
3. Presence of other malignancies (with the exception of any type of carcinoma in situ that has been completely resected, basal cell and squamous cell skin cancers, or other tumors/cancers that have been treated with curative intent and have been disease-free for at least 3 years).
4. A history of anti-tumor treatment that meets any of the following criteria:

（1）Received traditional Chinese medicine or patent medicine with anti-tumor indications within 1 week prior to the first dose of the study drug; （2）Underwent radiotherapy targeting the lung fields and whole brain within 4 weeks prior to the first dose of the study drug, or received radiotherapy targeting other areas (excluding the lung fields and whole brain) within 2 weeks prior to the first dose. Palliative radiotherapy for bone metastases to relieve pain or prevent skeletal-related events is excluded; （3）Underwent major surgery within 4 weeks, or has not recovered from the adverse effects of these surgeries. Thoracoscopic biopsy and mediastinoscopy are not considered major surgeries, and patients may be enrolled ≥1 week after the procedure 5. Has not recovered from any toxicity or complications of prior chemotherapy, surgery, radiotherapy, or other anti-tumor treatments, i.e., not reduced to ≤Grade 1 (NCI-CTCAE v5.0), with the exception of alopecia and permanent radiation-induced damage that cannot be recovered; 6. Requires the use of strong inhibitors or inducers of cytochrome P450 3A4 enzyme 1 week prior to the first dose of the study drug and during the study period.

7\. Has any severe or uncontrolled systemic disease, including but not limited to:

1. Uncontrolled hypertension, with the allowance for the initiation or adjustment of antihypertensive medications prior to screening;
2. Positive for anti-HIV, or positive for both anti-HCV and HCV-RNA, or positive for HBsAg with HBV-DNA ≥500 IU/mL
3. Active keratitis or ulcerative keratitis during the disease phase;
4. Active tuberculosis;
5. Active infection requiring systemic antimicrobial therapy within 2 weeks prior to the first dose of the study drug;
6. Other severe medical conditions or psychiatric disorders, or laboratory abnormalities that, in the investigator's judgment, make the study drug unsuitable for the patient or affect protocol compliance; 8. Cardiac dysfunction and diseases that meet any of the following criteria:

（1）The average corrected QT interval calculated by the Fridericia formula from three electrocardiograms during the screening period \>470 ms; （2）Any significant arrhythmias, such as ventricular arrhythmias, uncontrolled supraventricular or junctional arrhythmias, and other uncontrolled cardiac arrhythmias （3）Any risk factors for QTc prolongation, such as severe hypokalemia, hereditary long QT syndrome, or use of drugs that prolong the QT interval; d) Congestive heart failure with New York Heart Association (NYHA) classification ≥3; echocardiography indicating left ventricular ejection fraction (LVEF) \<50%； 9. History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring corticosteroid therapy, or is currently receiving drug therapy or other clinical interventions, or has active interstitial lung disease; 10. Has coagulation dysfunction or bleeding tendency 11. Has difficulty swallowing, or has active gastrointestinal disease, or has undergone major gastrointestinal surgery that may significantly affect the intake or absorption of the study drug 12. Has pleural effusion, pericardial effusion, or ascites that require drainage and/or are associated with dyspnea within 4 weeks prior to the first dose of the study drug; 13. Has any clinically significant systemic disease that requires treatment, as judged by the investigator, including but not limited to thyroid disease, organ transplant recipients, history of psychiatric disorders, history of drug abuse/addiction, alcoholism, or drug use; 14. History of acute or chronic pancreatitis, pancreatic surgery, or risk factors that may increase the risk of pancreatitis; 15. Patients receiving thrombolytic therapy are not eligible for inclusion, but patients receiving anticoagulant therapy may be included, provided that they have been on a stable dose of anticoagulant therapy for at least 1 week prior to the first dose; 16. Has a known hypersensitivity to the study drug or its excipients; 17. Pregnant or breastfeeding women; 18. Currently enrolled in another study device or study drug treatment, or received other study drugs or study devices within 2 weeks prior to the first dose of the study drug; 19. Cognitive impairment that may limit their understanding or execution of the informed consent form; 20. Presence of any condition that may increase the risk associated with the administration of the study drug, or may affect the interpretation of study results, or poor compliance with the study protocol, or any other situation that the investigator deems unsuitable for enrollment.

Where this trial is running

Neimeng, Neimeng and 11 other locations

• Ordos Central Hospital — Neimeng, Neimeng, China (Not_yet_recruiting)
• Peking University Cancer Hospital (Inner Mongolia Campus) — Neimeng, Neimeng, China (Not_yet_recruiting)
• Affiliated Hospital of Hebei University — Baoding, China (Not_yet_recruiting)
• Baotou Cancer Hospital — Baotou, China (Recruiting)
• Peking University Cancer Hospital & Institute — Beijing, China (Recruiting)
• Beijing Chest Hospital, Capital Medical University — Beijing, China (Not_yet_recruiting)
• Beijing Daxing District People's Hospital — Beijing, China (Not_yet_recruiting)
• Peking Union Medical College Hospital — Beijing, China (Not_yet_recruiting)
• Peking University People's Hospital — Beijing, China (Not_yet_recruiting)
• Peking University Third Hospital — Beijing, China (Not_yet_recruiting)
• The Second Hospital of Dalian Medical University — Dalian, China (Not_yet_recruiting)
• Tianjin Medical University Cancer Institute & Hospital — Tianjin, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Minglei Zhuo

Conditions Non Small Cell Lung Cancer NSCLC